Stenocare AS (OCSE:STENO) ROCE % : -504.34% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Stenocare AS ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Stenocare AS's annualized ROCE % for the quarter that ended in Dec. 2024 was -504.34%.

Stenocare AS ROCE % Historical Data

The historical data trend for Stenocare AS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stenocare AS ROCE % Chart

Stenocare AS Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-36.41

-29.83

-46.39

-56.09

-169.23

Stenocare AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-59.31	-52.97	-68.18	-92.01	-504.34

Stenocare AS ROCE % Calculation

Stenocare AS's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-33.061	/	( ( (38.12 - 11.254)	+	(19.436 - 7.229) )	/ 2 )
	=	-33.061	/	( (26.866	+	12.207)	/ 2 )
	=	-33.061	/	19.5365
	=	-169.23 %

Stenocare AS's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-85.572	/	( ( (26.27 - 4.543)	+	(19.436 - 7.229) )	/ 2 )
	=	-85.572	/	( ( 21.727	+	12.207 )	/ 2 )
	=	-85.572	/	16.967
	=	-504.34 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Stenocare AS (OCSE:STENO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Stenocare AS ROCE % Related Terms

Thank you for viewing the detailed overview of Stenocare AS's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Stenocare AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Stenocare AS (OCSE:STENO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Nyholmsvej 4, Randers NØ, DNK, 8930

Website

https://www.stenocare.com

Stenocare AS is a Danish company engaged in the cultivation and production of medical cannabis products through pharmacies and hospitals. The Company's business operations include the distribution and sales of imported products to several markets which also includes local cultivation and production of its medical cannabis products. Stenocare is well positioned to become a market leader in Denmark and a vendor in Europe. The Company is a supplier of medical cannabis oil for patients in Denmerk, Sweden, UK, Australia and Norway. It has an indoor production facility for the cultivation and production of medical cannabis at Randers, Denmark.

Stenocare AS Headlines

No Headlines